CTOs on the Move

NPS Pharmaceuticals

www.npsp.com

 
NPS Pharmaceuticals is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.npsp.com
  • 550 Hills Dr
    Bedminster, NJ USA '07921
  • Phone: 908.450.5300

Executives

Name Title Contact Details

Similar Companies

Rodin Therapeutics

Rodin Therapeutics is a Biotechnology company located in Cambridge, Massachusetts, United States.

Quincy Bioscience

Quincy Bioscience is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Liberty BioSecurity

Liberty BioSecurity’s multi-disciplinary research teams transform life science discoveries into global-class, industry leading solutions.

ABclonal

Based in Massachusetts, ABclonal is a dynamic and growing provider of biology research reagents and services. With scientists from world-class universities, we thrive to improve the quality of life science research by providing high-quality antibodies, proteins, ELISA kits, NGS Prep Kits and molecular enzymes.

Zymeworks

Zymeworks (NASDAQ:ZYME) is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks` suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks` lead clinical candidate, zanidatamab, is a novel Azymetric™ HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks` second product candidate, Zanidatamab Zovodotin (ZW49), is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks` proprietary ZymeLink™ linker-cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies.